Fexofenadine
摘要:
Fexofenadine , the active metabolite of terfenadine, is a selective histamine Hi receptor antagonist that does not cross the blood brain barrier and appears to display some anti-inflammatory properties. Fexofenadine is rapidly absorbed (onset of relief ≈2 hours) and has a long duration of action, making it suitable for once daily administration. Clinical trials (≤2 weeks' duration) have shown fexofenadine 60mg twice daily and 120mg once daily to be as effective as loratadine 10mg once daily, and fexofenadine 120mg once daily to be as effective as cetirizine 10mg once daily in the overall reduction of symptoms of seasonal allergic rhinitis. When given in combination, fexofenadine and extended release pseudoephedrine had complementary activity. Fexofenadine was effective in relieving the symptoms of sneezing, rhinorrhoea, itchy nose, palate or throat, and itchy, watery, red eyes in patients with seasonal allergic rhinitis. There were often small improvements in nasal congestion that were further improved by pseudoephedrine. Fexofenadine produced greater improvements in quality of life than loratadine to an extent considered to be clinically meaningful, and enhanced patients' qualty of life when added to pseudoephedrine treatment. Although no comparative data with other H 1 antagonists exist, fexofenadine 180mg once daily was effective in reducing the symptoms of chronic idiopathic urticaria for up to 6 weeks. Fexofenadine was well tolerated in clinical trials in adults and adolescents and the adverse event profile was similar to placebo in all studies. The most frequently reported adverse event during fexofenadine treatment was headache, which occurred with a similar incidence to that seen in placebo recipients. Fexofenadine does not inhibit cardiac K+ channels and is not associated with prolongation of the corrected QT interval. When given alone or in combination with erythromycin or ketoconazole, it was not associated with any adverse cardiac events in clinical trials. As it does not cross the blood brain barrier, fexofenadine is free of the sedative effects associated with first generation antihistamines, even at dosages of up to 240 mg/day. Conclusions: fexofenadine is clinically effective in the treatment of seasonal allergic rhinitis and chronic idiopathic urticaria for which it is a suitable option for first-line therapy. Comparative data suggest that fexofenadine is as effective as loratadine or cetirizine in the treatment of seasonal allergic rhinitis. In those with excessive nasal congestion the combination of fexofenadine plus pseudoephedrine may be useful. In clinical trials fexofenadine is not associated with adverse cardiac or cognitive/psychomotor effects. Pharmacodynamic Properties Fexofenadine is a selective histamine H 1 receptor antagonist. Single doses 12 years. In the UK, the recommended dosage of fexofenadine for relief of symptoms of seasonal allergic rhinitis is 120mg once daily and the recommended dosage for the treatment of chronic idiopathic urticaria is 180mg once daily. For patients with decreased renal function or those on haemodialysis a lower starting dosage of 60mg once daily is recommended in the US, but not in the UK. Dosage adjustment is not necessary in elderly patients or those with hepatic impairment.
展开
关键词:
fexofenadine Allegra Telfast Fastofen Tilfur Vifas 83799‐ 24‐ 0 drug animal metabolism human metabolism
DOI:
10.2165/00003495-200059020-00020
被引量:
年份:
2000
通过文献互助平台发起求助,成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用!